E. Kunder
7 Papers
17 Citations
E. Kunder is an academic researcher. The author has contributed to research in topics: Placebo & BASDAI. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study
Mazurov Vi,Shandor Erdes,E. Kunder,N. Soroka,Pavel Shesternya,S. Smakotina,T. Raskina,D. G. Krechikova,Tatiana Dubinina,A. Eremeeva,E. Dokukina,E. Chernyaeva,Roman Ivanov +12 more
TL;DR: Treatment with BCD-085 leads to significant improvement in all AS symptoms in comparison with placebo, and the drug was well tolerated in all doses with no differences with placebo in safety profiles.
10
Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study.
V. Mazurov,Tatiana V. Dubinina,Shandor Erdes,S A Lapshina,N. Soroka,E. Kunder,A. V. Smirnov,A. Eremeeva,A V Zinkina-Orikhan,M.A. Morozova,Inna Gaydukova +10 more
TL;DR: Subcutaneous netakimab is effective in patients with r-axSpA irrespective of baseline CRP and inflammation on SIJ MRI, with a trend towards the most prominent improvement in ASDAS-CRP and BASDAI for patients with CRP >20 mg/L.
7
FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximab
L. Denisov,Ivan G. Gordeev,Mazurov Vi,Alexander Lila,E. Zonova,O. Nesmeyanova,Elena Ilivanova,T. Plaksina,A. Eremeeva,A. Artemeva,E. Chernyaeva,Roman Ivanov,S Pimanov,E. Kunder,N. Soroka +14 more
TL;DR: Results from three clinical trials of infliximab biosimilar, BCD-055 are presented, including comparative data on pharmacokinetics, efficacy and safety in a variety of patient populations.
4
THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study
Alexander Lila,L. Denisov,T. Plaksina,S. Smakotina,E. Kunder,N. Soroka,A. Kastanayan,O. Nesmeyanova,O. Antipova,Elena Ilivanova,A. Eremeeva,E. Dokukina,E. Chernyaeva,Roman Ivanov +13 more
TL;DR: Treatment with BCD-055 and INF innovator leads to significant decline in RA activity and inflammatory markers by Wk14, which corresponds with previous results of ACR20 assessment.
2
Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA
Tatiana Dubinina,A. Demina,E. Agafonova,Shandor Erdes,Vadim I. Mazurov,I Z Gaydukova,Andrey Pristrom,E. Kunder,N. F. Soroka,A. Kastanayan,T. Povarova,Elena Zhugrova,T. Plaksina,Pavel Shesternya,T. Kropotina,O. V. Antipova,Elena A Smolyarchuk,O. A. Tsyupa,Diana Abdulganieva,S. A. Lapshina,Diana G Krechikova,I. Gordeev,O. Nesmeyanova,V. V. Tyrenko,Elena P. Ivanova,Aleksandra Strelkova +25 more
TL;DR: Back pain (BASDAI question 2) and nocturnal back pain decreased steadily during the entire follow-up period compared to the screening values and NTK is an effective therapy for active AS that improves QoL scores, significantly reduces pain intensity and improves work productivity.
2